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Abstract
Polymorphisms in ADAM33, the first gene identified in asthma by positional cloning, have been recently associated with
psoriasis. No replication study of this association has been published so far. Data available in the French EGEA study
(Epidemiological study on Genetics and Environment of Asthma, bronchial hyperresponsivensess and Atopy) give the
opportunity to attempt to replicate the association between ADAM33 and psoriasis in 2002 individuals. Psoriasis (n=150)
has been assessed by questionnaire administered by an interviewer and a sub-sample of subjects with early-onset psoriasis
(n=74) has been identified based on the age of the subjects at time of interview (,40 years). Nine SNPs in ADAM33 and 11
SNPs in PSORS1 were genotyped. Association analysis was conducted by using two methods, GEE regression-based method
and a likelihood-based method (LAMP program). The rs512625 SNP in ADAM33 was found associated with psoriasis at
p=0.01, the usual threshold required for replication (OR [95% CI] for heterozygotes compared to the reference group of
homozygotes for the most frequent allele=0.61 [0.42;0.89]). The rs628977 SNP, which was not in linkage disequilibrium with
rs512625, was significantly associated with early-onset psoriasis (p=0.01, OR [95% CI] for homozygotes for the minor allele
compared to the reference group=2.52 [1.31;4.86]). Adjustment for age, sex, asthma and a PSORS1 SNP associated with
psoriasis in the EGEA data did not change the significance of these associations. This suggests independent effects of
ADAM33 and PSORS1 on psoriasis. This is the first study that replicates an association between genetic variants in ADAM33
and psoriasis. Interestingly, the 2 ADAM33 SNPs associated with psoriasis in the present analysis were part of the 3-SNPs
haplotypes showing the strongest associations in the initial study. The identification of a pleiotropic effect of ADAM33 on
asthma and psoriasis may contribute to the understanding of these common immune-mediated diseases.
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Introduction
Psoriasis is an inflammatory disease of the skin, phenotypically
heterogeneous, characterized by hyperproliferation and remodeling,
often expressed by chronic plaque-type [1,2]. It is a multifactorial
disease, with a genetic basis and with environmental factors involved
in exacerbating or in triggering the disease [3]. Strongly associated
with the major histocompatibility complex, especially for early-onset
forms, this auto immune disease exhibits a Th1 dominant cytokine
profile, with an important role of various interferon responses [4].
Environmental triggers include bacterial skin infections and tissue
injury. Its association with other disorders, such as Crohn’s disease,
arthritis, diabetes and coronary heart disease [5] support the
hypothesis of common genes with other diseases. Multiple genome-
wide linkage analyses and genetic association analyses have been
performed in order to elucidate the genetic component of psoriasis.
There is still limited evidence of the implication of other genes than
PSORS1, located in the MHC region [6], but the role of several other
genes has been suggested [7,8]. Recently a genome-wide scan in
French extended families of psoriasis confirmed the presence of a
psoriasissusceptibilitylocusonchromosome20p13[9],andidentified
by positional cloning the ADAM33 gene (A Disintegrin And
Metalloproteinase 33) as a psoriasis susceptibility gene [10]. ADAM33
was the first gene identified in asthma by positional cloning [11]. Its
function is not well understood, but has a putative role in airway
remodelling [12]. The association of ADAM33 with asthma has been
confirmed in some studies, but not all. No replication study on the
association between genetic variations in ADAM33 and psoriasis has
been published so far.
The aim of the present paper was to attempt to replicate the
association between polymorphisms in the ADAM33 gene and
psoriasis, taking advantage of data collected in the French
Epidemiological study on the Genetics and environment of
Asthma (EGEA), a study in which no association of ADAM33
with asthma was observed [13].
Results
Among the 2002 subjects included in the present analysis, 150
had psoriasis (7.5%) and half of the subjects with psoriasis had
early-onset psoriasis (n=74). Subjects with psoriasis were older
than those without psoriasis (Table 1).
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inant model for each SNP effect, one SNP, rs512625, showed
association with psoriasis that reached the 1% significance level
classically required for replication (Table 2). Heterozygotes for this
SNP had a decreased risk for psoriasis as compared to the
reference group of homozygotes for the most frequent allele
(OR=0.61 [0.42; 0.89]) (Table 3). Moreover, a dominant model
was rejected against the general codominant model (p=0.02).
When examining early-onset psoriasis, we found association with
another SNP, rs628977, at the 1% level (Table 2). Homozygotes
for the minor T allele had a higher risk for early-onset psoriasis as
compared to the reference group (OR=2.52 [1.31; 4.86])
(Table 3). A recessive model for rs628977 (which fits the data,
p=0.55) increased the significance (p=0.003). Two polymor-
phisms in the PSORS1 gene, rs3131000 and rs3130559, were
associated with psoriasis (p,0.01; Supplementary, Table S1).
None of these two SNPs was significantly associated with early-
onset psoriasis.
The effects on psoriasis of the two ADAM33 SNPs found
associated with the disease in the univariate analysis were then
tested by multivariate analysis adjusting for the effects of age, sex,
asthma and rs3131000, one of the most strongly psoriasis-
associated PSORS1 SNP in our data (Table 3). Association of
rs512625 with psoriasis and the OR estimate in heterozygotes
remained unchanged as compared to the univariate analysis
(Table 3). Similarly, rs629877 remained associated with early-
onset psoriasis with homozygotes for the T allele showing an
increased risk (p=0.004) (table 3). Moreover, repeating the
multivariate analysis by adjusting for the other PSORS1 SNP
associated with psoriasis (rs3130559) led to the same results (data
not shown).
Since low linkage disequilibrium (LD) was observed between
rs628977 and rs512625 (LD coefficient D9=0.34; see online
supplement Table S2), we conducted a two-SNP analysis for both
psoriasis and early-onset psoriasis by including these two
polymorphisms in the regression model. This 2-SNP analysis
showed that these polymorphisms were jointly associated to both
psoriasis and early-onset psoriasis and had statistically independent
effects, these effects being of the same order of magnitude as in the
single-SNP analyses (Table 3). A stratified analysis on rs512625
genotypes indicated an excess risk for psoriasis in TT homozygotes
for rs628977 that was similar for each rs512625 genotypic class
(results not shown). This suggests there is no interaction between
these 2 SNPs.
Analyses were also repeated with a recently proposed likelihood-
based method that can take into account the whole family
structures and conditions upon the observed affection status, as
implemented in the LAMP program [14,15]. This approach
confirmed the association between rs512625 and psoriasis
(p=0.007 for the 2 df likelihood-ratio test under a general
codominant model for the SNP effect) with a protective effect in
heterozygotes as found before with the regression approach (ratio
of penetrances of GA versus GG=0.62). This method also showed
an association between rs628977 and early-onset psoriasis
(p=0.03 for the 2 df test) with an increased risk in TT
homozygotes (ratio of penetrances of TT versus CC=2.23) (results
not shown).
Discussion
For the first time, an association between ADAM33 and psoriasis
initially observed in French families of psoriasis is replicated [10].
Interestingly, rs512625, the ADAM33 SNP showing the strongest
association with psoriasis considered as a whole in the present
analysis, was also among the SNPs showing the strongest
association with psoriasis by single SNP and haplotype analyses
in the initial study [10]. Another SNP, rs628977, was specifically
associated with early-onset psoriasis in the present analysis. This
locus has not been identified by the single-SNP analysis conducted
by Lesueur et al. [10], but this SNP was part of the 3-SNPs
haplotypes showing the strongest associations with psoriasis. In
both studies, the T allele was associated with an increased risk for
psoriasis (or early-onset psoriasis, as detected here). Our results
also suggest that these two ADAM33 SNPs have independent
effects on psoriasis.
Estimates of the odds-ratios for rs512625 showed a protective
effect on psoriasis in heterozygotes but not in homozygotes for the
minor allele. This decreased in risk observed in heterozygotes only
may result from a more complex underlying model involving
interactions between SNPs at a given locus or with other factors.
This is in line with the results of the initial study [10] where the
most significant association was observed in the 3-SNPs haplotype
analysis.
The present analysis has been performed in a large case-control
and family study for asthma and asthma-related phenotype
(EGEA). In this population, the frequency of psoriasis was 7.5%,
higher than the prevalence of psoriasis expected in Caucasian
populations (2–4%) [16]. It may be explained by two comple-
mentary aspects: 1) The EGEA data, composed of 388 asthmatic
cases and their first degree relatives and controls, is not
representative of a population-based study; 2) It has been
previously shown that questionnaire-based assessment of psoriasis
Table 1. Description of the population.
No psoriasis,
n=1852
Psoriasis, all
n=150
Psoriasis with early-onset
(,40 years), n=74
p* between all psoriasis and
no psoriasis
Sex, % males 51.1 52.7 50.0 0.73
Age, m6sd 38.8617.9 44.6615.9 32.2611.3 0.0002
Age, ,40 years % 52.2 34.7 ,0.0001
Smoking:
Never smokers, % 50.7 40.7 45.7 0.07
Ex-smokers, % 24.9 27.6 20.0
Current smokers, % 24.4 31.7 34.3
Asthma, % 44.3 36.7 37.8 0.05
*p value assessed using GEE model.
doi:10.1371/journal.pone.0002448.t001
ADAM33 and Psoriasis
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2448leads to an over-estimate of the prevalence compared to
dermatological examination-based assessment of psoriasis [17].
Nevertheless, the significant associations observed between
psoriasis and SNPs in PSORS1, one locus identified consistently
by several linkage and association studies, indicates a good validity
of the psoriasis phenotype in the EGEA study.
The sub-sample of early-onset psoriasis has been identified using
the age of the subjects at time of interview since age at onset was
not recorded in the EGEA study. Consequently, psoriasis patients
aged 40 years and older cannot be identified as late-onset psoriasis
since they include subjects with both early-onset and late-onset
psoriasis. Although it has been previously shown that HLA-cw6
(PSORS1) is more specifically associated with an earlier age of
onset, 2 PSORS1 SNPs were found significantly associated with
psoriasis considered as a whole in the EGEA study but none of
them was significantly associated with early-onset psoriasis. The
lack of association between PSORS1 SNPs and early-onset psoriasis
in the EGEA study may result from a lack of power since the ORs
observed for rs3131000 genotypes were higher when considering
early-onset psoriasis than psoriasis as a whole. Regarding
ADAM33, the rs628977 SNP was more specifically associated
with early-onset psoriasis. As previously observed for HLA-cw6,
SNPs in ADAM33 may also be more specifically associated with
early-onset psoriasis.
The analysis conducted allowed to adjust for potential
confounders. Interestingly, after adjustment on PSORS1 polymor-
phisms, the association between ADAM33 and psoriasis remained
significant. In agreement with results from Lesueur et al, ADAM33
and PSORS1 seem to be independently involved in psoriasis.
The function of the ADAM33 gene is not yet well known, but
several arguments support the biological plausibility of an
association between psoriasis and ADAM33. ADAM33 is expressed
in airway smooth muscle and lung fibroblasts and also in the skin
[18]. In parallel, genetic variants in ADAM33 were found
associated with asthma and psoriasis, two diseases characterized
by tissue remodelling. This is consistent with a pleiotropic effect of
this gene. There is active on-going research regarding ADAM33
and the functional role of various SNPs starts to be unravelled
[19]. Of interest, in the context of psoriasis, a Th1 disease, is the
demonstration of a down regulation of the expression of ADAM33
by IFNG (Interferon-gamma), the prototypical Th1 cytokine, in
airway smooth muscle cells [20]. Immunological control in
psoriasis is complex and increasing evidence supports that not
only Th1, but also Th17, may play a major role in the control of
epidermal hyperplasia [21,22]. The independent association of
PSORS1 with other genes, such as ADAM33, is coherent with the
role of various processes including adaptative and innate
immunity, inflammation and remodelling in the occurrence and
perpetuation of psoriasis, a complex disease.
Further research is needed to further replicate the present
association, to assess potential associations in various psoriasis
subtypes by studying larger samples and to understand the
potential regulation of ADAM33 at the epidermal level. The
identification of a pleiotropic effect of ADAM33 on asthma and
Table 2. Test of association of psoriasis and early-onset psoriasis with ADAM33 and PSORS1 SNPs under a general genetic model
using the GEE method.
SNP Location (bp)
Nucleotide change
Ref. allele.alt. allele MAF* Psoriasis p value**
Early-onset psoriasis
p value**
ADAM33
rs6084432 3583653 G.A 0,15 0.80 0.15
rs512625 3588378 G.A 0,29 0.01 0.06
rs677044 3589431 A.G 0.23 0.33 0.15
rs543749 3589679 G.T 0.12 0.83 0.41
rs628977 3589721 C.T 0.38 0.10 0.01
rs2787095 3595943 G.C 0.38 0.69 0.06
rs554743 3602142 C.T 0.27 0.32 0.37
rs2853215 3606255 G.A 0.27 0.79 0.07
rs4815596 3611800 G.A 0,13 0.73 0.98
PSORS1
rs2284177 31197574 G.C 0,21 0.69 0.72
rs3131000 31199252 G.C 0,41 0.03 0.12
rs3094207 31199388 C.G 0,36 0.07 0.08
rs3094205 31199841 A.G 0,36 0.08 0.10
rs3095307 31200028 G.C 0,44 0.79 0.72
rs3094198 31201306 A.G 0,48 0.58 0.60
rs3130558 31205162 C.G 0,25 0.18 0.56
rs3130559 31205280 C.T 0,22 0.01 0.47
rs3130560 31205432 T.G 0,26 0.26 0.63
rs3823418 31208921 G.A 0,21 0.86 0.43
rs2074478 31213612 C.T 0,17 0.99 0.97
*Minor Allele Frequency.
**p value for a general genetic model (2df).
doi:10.1371/journal.pone.0002448.t002
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immune-mediated diseases.
Materials and Methods
Psoriasis has been assessed by questionnaire administered by an
interviewer in more than 2000 subjects included in the EGEA
study with a positive answer to ‘Have you ever been treated or
followed for psoriasis’’. The first EGEA survey (EGEA1) has been
conducted from 1991 to 1995 and the protocol and descriptive
characteristics have been described elsewhere [23,24]. Briefly, 388
families of asthmatic cases were recruited in chest clinics of six
clinical centers and 415 controls were recruited mostly in electoral
rolls and also in surgery departments and a check-up center. One
of the first genome screens for asthma has been conducted in
EGEA [25]. A twelve year follow-up of the study (EGEA2) has
been conducted for 2003 to 2006. Among the alive cohort, 92%
(n=1845) completed a short self-questionnaire and 77%
(n=1543) participated to the second phase of the study. In
addition, 58 new family members where included in the study at
the second survey. Written consent was obtained from all
participants at both surveys. Ethical approval to carry out the
study was obtained for both surveys from the relevant committees
(Cochin Royal Hospital, Paris for Egea1 and Necker-Enfants
Malades Hospital, Paris for Egea2).
As part of a panel of asthma candidate genes, 9 SNPs belonging
to ADAM33 gene were genotyped in 2009 subjects using either
Taqman Probes (Applied Biosystems, Foster City, California) on
an AB17900HT Sequence Detection System or 1536-plex
Illumina GoldenGate assay (Illumina, San Diego, CA) at the
Centre National de Ge ´notypage (CNG, Evry, France). Moreover,
in the context of HLA region genotyping using Illumina
GoldenGate assay, a total of 11 SNPs within PSORS1 gene were
available in our data for 1203 subjects. The consistency of the SNP
data with Mendelian inheritance was evaluated using the
PedCheck program [26]. Test of Hardy-Weinberg equilibrium
was performed using an exact test [27]. No SNP showed Hardy-
Weinberg disequilibrium.
The present analysis has been conducted on 2002 individuals
with available data on both psoriasis and at least one polymor-
phism in the ADAM33 gene.
Statistical analyses
The association between psoriasis and polymorphisms of
ADAM33 and PSORS1 genes was assessed using two complemen-
tary statistical methods: 1) a logistic regression model taking into
account familial dependence of the observations (GEE model.
Proc GENMOD using SAS statistical software); 2) a likelihood-
based method taking into account the whole family structures and
conditioning upon the observed affection status (implemented in
LAMP program) [14,15]. The effect of each SNP on disease
(univariate analysis) was tested under a general genetic model (2
degrees of freedom test) and the odds-ratios (ORs) (or ratios of
penetrances using LAMP) were calculated using as reference
group the homozygotes for the most frequent allele. Multivariate
analyses were conducted using the GEE regression approach.
These multivariate analyses allowed testing for SNP effect while
adjusting for age, sex and asthma, three characteristics signifi-
cantly associated with psoriasis in the EGEA data, and for
genotypes at rs3131000, the PSORS1 SNP most strongly associated
with psoriasis in our data. Multiple regression analysis was also
used to test for the effect of multiple ADAM33 markers on
psoriasis.
Since two types of psoriasis have already been widely described
according to the age of onset, before or after age 40, we identified
a sub-sample of psoriasis with early-onset psoriasis based on the
age of the subjects at time of interview (age of onset of psoriasis was
not recorded): early-onset psoriasis consisted of the sub sample of
individuals younger than 40 years of age when they replied
positively to the psoriasis question [3,28]. However, psoriasis
patients older than 40 years of age could not be considered as late-
onset psoriasis. Association analyses were thus carried out by
examining either psoriasis as a whole or early-onset psoriasis in
subjects less than 40 years old.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0002448.s001 (0.04 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0002448.s002 (0.04 MB
DOC)
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